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Abstract Serum alphafetoprotein was estimated in fetuses with and without Down's syndrome or with other chromosome abnormalities from the 17th to the 28th week of pregnancy. In normal fetuses, the AFP level declines steadily during this period. Before 20 weeks, there was no difference in the serum AFP levels of the three groups of fetuses. After 20 weeks, the serum AFP level in cases of Down's syndrome declined more rapidly than normal. This was not observed in fetuses with other chromosome abnormalities. This suggests that low maternal serum alphafetoprotein levels used for prenatal screening for Down's syndrome in the early second trimester cannot be explained by low levels in the Down's fetuses themselves.
It is now well established that midtrimester maternal serum alphafetoprotein (MSAFP) levels tend to be lower than normal when the fetus has Down's syndrome. 1-6 Some workers have found that the amniotic fluid alphafetoprotein (AFAFP) levels are below the normal median in such cases too,2 58 while others have found them to be normally distributed. ' 4 The mechanism for these low AFP levels in the maternal serum, and possibly the amniotic fluid, is not yet known, but one suggestion has been that Down's syndrome fetuses produce less AFP than normal fetuses.9 My previous studyl' suggested that this is not so; consequently, I Cordocentesis samples from fetuses without Down's syndrome were divided into two groups and their results were also analysed separately. Group 1 (41 samples) comprised fetuses which were completely normal, both chromosomally and developmentally. These were derived from patients undergoing the procedure for raised maternal age who presented too late for amniocentesis, or where the amniotic cell culture had failed, or where the fetus was at risk for a blood disorder. Group 2 (49 samples) consisted of fetuses who were chromosomally normal but who had a developmental defect, such as diaphragmatic hernia, hydrocephalus, congenital heart defect, or exomphalos, or there was an obstructive uropathy or Rhesus incompatibility. Samples were also received from fetuses with renal agenesis, ascites, hydrops, and intrauterine growth retardation, but they were excluded from the study.
All postmortem specimens of fetuses with Down's syndrome were derived from termination of pregnancy after prenatal diagnosis. Seven fetuses without Down's syndrome also came from terminations: five had a neural tube defect and two were normal. Serum AFP results from these were pooled with those obtained from 16 The length of gestation was calculated from the first day of the last menstrual period and correlated with the estimate of fetal age from ultrasound scan. Those in which there was no major discrepancy between the two were used.
The Mann-Whitney test was used to compare results from affected and unaffected pregnancies, directly for 19 and 20 weeks' gestation, and modified as described below for 21 to 28 weeks.
Results
Fetal serum AFP values were obtained for each week of pregnancy from 17 to 28 weeks. Results are presented from three different groups of fetuses without Down's syndrome: on fresh blood from completely normal fetuses (group 1), fresh samples from chromosomally normal but developmentally abnormal fetuses (group 2), and postmortem samples (group 3). All three groups of fetuses without Down's syndrome showed similar results (fig 1) , although at some time points there were few samples. Thus, Similarly, at 19 to 20 weeks when there were both fresh and postmortem samples of Down's syndrome cases analysed, the results were comparable.
In normal fetuses the serum AFP level declined steadily and gradually over the observation period from a mean value of 2800 [ig/ml at 17 weeks and 2202 pg/ml at 18 weeks to 780 lig/ml at 28 weeks.
There are AFP values on 21 fetuses with Down's syndrome (fig 1) . At 19 and 20 weeks, the serum AFP levels of Down's syndrome fetuses were evenly distributed within the normal range and there was no significant difference between the two groups (p=0-60 for 19 weeks, p=056 for 20 weeks). By contrast, at 21 and 22 weeks, the AFP levels of all five cases of Down's syndrome fell in the lower half of the normal ranges, and at 26 weeks and 27 weeks the Down's AFP levels were below the values for normal fetuses. The numbers for each week are small, and so the results were analysed statistically by ranking (r) the values of the n samples for each fortnight I  17  18  19  20  21  22  23  24  25  26  27  28 Gestation (weeks) It is believed that MSAFP is derived from the fetal unit, and a major route is through the membranes from the amniotic fluid. Although in neural tube defects there is only a relatively weak correlation between high AFAFP levels and the corresponding MSAFP levels,'6 presumably, in the case of Down's syndrome, the low maternal serum levels do reflect the low amniotic fluid levels.
If the normal fetal serum AFP levels I have found in Down's syndrome fetuses in the early second trimester truly reflect normal liver AFP production, then an explanation for the aberrant AFP levels now perhaps has to be found at the interface of the fetus and the amniotic fluid. In the midtrimester, amniotic fluid is thought to derive its AFP mainly through fetal micturition. The possibility must now exist that excretion of AFP through the kidney is retarded in Down's syndrome fetuses in the midtrimester.
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